E

Enodia Therapeutics

Latest funding round: 23 M$

E

• City : Paris
• Round : Seed
• Sector : Health
• Sector : AI

Enodia develops small molecules that selectively degrade disease-causing proteins as they are synthesised, using a machine-learning platform. Its programmes target inflammatory and autoimmune diseases, aiming to act before these proteins cause damage.